Julia Fioretti
Stories by Julia Fioretti
Tencent Music raises nearly $1.1b in US IPO
The music arm of gaming and social network giant Tencent Holdings Ltd priced its American Depositary Receipts (ADRs) at $13 per share, at the low end
China’s Junshi Biosciences seeks up to $414m in Hong Kong IPO
The company could raise as much as $476 million if a greenshoe, or over-allotment option - is exercised within the first month of trading.
Hong Kong may take global IPO crown but concerns mount over new listings’ performance
Companies listing in Hong Kong have sold shares worth $31.4 billion so far this year, the highest total in eight years, compared with $30.2 billion
Tencent Music launches $1.2b US IPO, eyes up to $25b valuation
The music streaming giant is selling 82 million American Depositary Receipts (ADRs) in a range of between $13 and $15 each.
Alibaba-backed Babytree said to scrape bottom of the barrel with Hong Kong IPO
The IPO will value Babytree at $1.5 billion, rather than the $2 billion valuation in late May when Alibaba invested $214 million.
Tencent Music’s $2b US IPO plans hang in the balance
The last mega U.S. IPO of the year faces a still-weak mood towards tech stocks and ongoing market jitters ahead of next week’s G20 meeting in Buenos
Crypto miner Canaan lets $400m Hong Kong IPO application lapse
Canaan's lapsed application comes two weeks after Hong Kong's SFC said it would bring "virtual assets" such as cryptocurrencies further within its reg
Alibaba-backed Babytree slashes Hong Kong IPO size, seeks up to $281m
Babytree had originally aimed to raise $1 billion in its initial public offering, but falling markets forced the company to lower its target.
Tencent-backed travel firm Tongcheng-Elong cuts HK IPO size as market tanks
The company had earlier been seeking to raise up to $1 billion, but weak markets and a slide in Ctrip's share price forced it to slash the size of the
Temasek-backed Innovent Biologics makes 5% gain in Hong Kong debut
It is the fourth listing under new rules in Hong Kong aimed at wooing early-stage drug developers.
